Professional
Added to YB: 2023-12-18
Pitch date: 2023-12-18
ILMN [bullish]
Illumina, Inc.
+2.67%
current return
Author Info
No bio for this author
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Market Cap
$18.4B
Pitch Price
$128.06
Price Target
228.00 (+73%)
Dividend
N/A
EV/EBITDA
15.81
P/E
27.05
EV/Sales
4.60
Sector
Life Sciences Tools and Services
Category
special_situation
Illumina: Plans to Divest Grail After U.S. Antitrust Case Faces More Hurdles
ILMN: $228 FV for genomic sequencing leader; $180 legacy ops, $48 Grail. Undervalued despite EU risks. $100 genome goal but new tech threats. Grail divestiture by mid-24 offers options. Moat: high R&D, 2000+ patents. Icahn activism drove refocus on core biz.
Read full article (9 min)